A Biotechnology Crossroads
By Becca Muir,
Science for the People
| 02. 01. 2021
Before Tina Stevens and Stuart Newman wrote Biotech Juggernaut, Newman helped Stevens fight legal action from an unexpectedly powerful adversary. Two scientists and the financer-author of Proposition 71, a 2004 California state initiative to fund stem cell medicine and promising imminent cures, wanted to prevent Stevens expressing her “false and misleading” views about the bill. Advocates said Proposition 71 would lead to miracle treatments for serious, debilitating illnesses such as Alzheimer’s, multiple sclerosis and heart disease. Using DNA from a patient and an egg donated by a healthy woman, researchers would produce embryonic stem cells that could then specialise and replace virtually any cell in the patient’s body.
But, Stevens, a bioethicist and historian, felt uneasy about the scientific and ethical claims of the proposition. She was part of a progressive wing of activists who were concerned about the serious risks posed to women who donated eggs for this research, as well as the troubling ethical implications of some of the techniques used. The type of stem cell research proposed in the proposition constituted a form of human cloning – somatic...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...
By Staff, The Medicine Maker | 03.21.2025
"The Promise and Peril of CRISPR" cover by Johns Hopkins University Press
As a paediatrician taking care of children with sickle cell disease, Neal Baer, a Harvard Medical School graduate, was in awe of the power of CRISPR technologies. Later...